Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016.

immunocompromised host infection control molecular epidemiology single room contact precautions transmission vancomycin-resistant enterococci

Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
01 2022
Historique:
entrez: 14 1 2022
pubmed: 15 1 2022
medline: 9 3 2022
Statut: ppublish

Résumé

BackgroundEvidence supporting the effectiveness of single-room contact precautions (SCP) in preventing in-hospital acquisition of vancomycin-resistant enterococci (haVRE) is limited.AimWe assessed the impact of SCP on haVRE and their transmission.MethodsWe conducted a prospective, multicentre cohort study in German haematological/oncological departments during 2016. Two sites performed SCP for VRE patients and two did not (NCP). We defined a 5% haVRE-risk difference as non-inferiority margin, screened patients for VRE, and characterised isolates by whole genome sequencing and core genome MLST (cgMLST). Potential confounders were assessed by competing risk regression analysis.ResultsWe included 1,397 patients at NCP and 1,531 patients at SCP sites. Not performing SCP was associated with a significantly higher proportion of haVRE; 12.2% (170/1,397) patients at NCP and 7.4% (113/1,531) patients at SCP sites (relative risk (RR) 1.74; 95% confidence interval (CI): 1.35-2.23). The difference (4.8%) was below the non-inferiority margin. Competing risk regression analysis indicated a stronger impact of antimicrobial exposure (subdistribution hazard ratio (SHR) 7.46; 95% CI: 4.59-12.12) and underlying disease (SHR for acute leukaemia 2.34; 95% CI: 1.46-3.75) on haVRE than NCP (SHR 1.60; 95% CI: 1.14-2.25). Based on cgMLST and patient movement data, we observed 131 patient-to-patient VRE transmissions at NCP and 85 at SCP sites (RR 1.76; 95% CI: 1.33-2.34).ConclusionsWe show a positive impact of SCP on haVRE in a high-risk population, although the observed difference was below the pre-specified non-inferiority margin. Importantly, other factors including antimicrobial exposure seem to be more influential.

Identifiants

pubmed: 35027104
doi: 10.2807/1560-7917.ES.2022.27.2.2001876
pmc: PMC8759111
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Références

JAMA. 2013 Oct 16;310(15):1571-80
pubmed: 24097234
J Clin Microbiol. 2016 Dec;54(12):2874-2881
pubmed: 27558178
Am J Infect Control. 2009 Mar;37(2):85-93
pubmed: 19249637
Infection. 2019 Feb;47(1):7-11
pubmed: 30178076
Antimicrob Agents Chemother. 2002 Jun;46(6):1619-28
pubmed: 12019066
MMWR Recomm Rep. 1995 Sep 22;44(RR-12):1-13
pubmed: 7565541
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jan;47(1):51-61
pubmed: 15205824
Lancet Infect Dis. 2019 Apr;19(4):410-418
pubmed: 30858014
N Engl J Med. 2011 Apr 14;364(15):1407-18
pubmed: 21488763
JAMA Intern Med. 2019 Nov 1;179(11):1501-1506
pubmed: 31424489
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62
pubmed: 30895215
N Engl J Med. 2000 Dec 28;343(26):1925-32
pubmed: 11136263
Infection. 2012 Dec;40(6):613-9
pubmed: 22665143
J Clin Microbiol. 2015 Dec;53(12):3788-97
pubmed: 26400782
J Hosp Infect. 2011 Mar;77(3):282-3
pubmed: 21288596
Open Forum Infect Dis. 2019 Mar 15;6(4):ofz139
pubmed: 31024976
Antimicrob Agents Chemother. 1996 Jun;40(6):1526-30
pubmed: 8726031
Antimicrob Agents Chemother. 2013 Jan;57(1):49-55
pubmed: 23070173
Infection. 2014 Dec;42(6):1013-22
pubmed: 25143193
Infect Control Hosp Epidemiol. 2011 May;32(5):490-6
pubmed: 21515980
Antimicrob Resist Infect Control. 2018 Apr 24;7:54
pubmed: 29760912
Am J Infect Control. 2018 Mar;46(3):333-340
pubmed: 29031432
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30782988
J Antimicrob Chemother. 2019 Jul 1;74(7):1776-1785
pubmed: 30929020
J Hosp Infect. 2010 Oct;76(2):97-102
pubmed: 20619929
Infect Drug Resist. 2015 Jul 24;8:217-30
pubmed: 26244026

Auteurs

Lena M Biehl (LM)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
German Centre for Infection Research, partner site Bonn-Cologne, Germany.

Paul G Higgins (PG)

German Centre for Infection Research, partner site Bonn-Cologne, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Jannik Stemler (J)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
German Centre for Infection Research, partner site Bonn-Cologne, Germany.

Meyke Gilles (M)

Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Silke Peter (S)

Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany.
German Centre for Infection Research, partner site Tübingen, Germany.

Daniela Dörfel (D)

Department of Haematology, Oncology and Immunology, Siloah hospital, Hannover, Germany.

Wichard Vogel (W)

Department of Oncology, Haematology, Immunology and Rheumatology, Internal Medicine II, University Hospital Tübingen, Tübingen, Germany.

Winfried V Kern (WV)

Division of Infectious Diseases, Department of Medicine II, University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Hanna Gölz (H)

Institute for Medical Microbiology and Hygiene, University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Hartmut Bertz (H)

Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Holger Rohde (H)

Institute for Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Germany.
German Centre for Infection Research, partner site Hamburg-Lübeck-Borstel, Germany.

Eva-Maria Klupp (EM)

Institute for Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Germany.

Philippe Schafhausen (P)

Department of Oncology and Haematology, Hubertus Wald Tumorzentrum/University Cancer Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Jon Salmanton-García (J)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Melanie Stecher (M)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
German Centre for Infection Research, partner site Bonn-Cologne, Germany.

Julia Wille (J)

Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Blasius Liss (B)

Department I of Internal Medicine, Helios University Hospital Wuppertal, Wuppertal, Germany.
Department of Internal medicine I, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.

Kyriaki Xanthopoulou (K)

Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Janine Zweigner (J)

Department of Hospital Hygiene and Infection Control, University Hospital of Cologne, Cologne, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Harald Seifert (H)

German Centre for Infection Research, partner site Bonn-Cologne, Germany.
Institute for Medical Microbiology, Immunology and Hygiene, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.

Maria J G T Vehreschild (MJGT)

Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
German Centre for Infection Research, partner site Bonn-Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH